RT Journal Article SR Electronic T1 Daily Forecasting of New Cases for Regional Epidemics of Coronavirus Disease 2019 with Bayesian Uncertainty Quantification JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.20.20151506 DO 10.1101/2020.07.20.20151506 A1 Lin, Yen Ting A1 Neumann, Jacob A1 Miller, Ely F. A1 Posner, Richard G. A1 Mallela, Abhishek A1 Safta, Cosmin A1 Ray, Jaideep A1 Thakur, Gautam A1 Chinthavali, Supriya A1 Hlavacek, William S. YR 2021 UL http://medrxiv.org/content/early/2021/01/19/2020.07.20.20151506.abstract AB To increase situational awareness and support evidence-based policy-making, we formulated a mathematical model for COVID-19 transmission within a regional population. This compartmental model accounts for quarantine, self-isolation, social distancing, a non-exponentially distributed incubation period, asymptomatic individuals, and mild and severe forms of symptomatic disease. Using Bayesian inference, we have been calibrating region-specific models daily for consistency with new reports of confirmed cases from the 15 most populous metropolitan statistical areas in the United States and quantifying uncertainty in parameter estimates and predictions of future case reports. This online learning approach allows for early identification of new trends despite considerable variability in case reporting.Article Summary Line We report models for regional COVID-19 epidemics and use of Bayesian inference to quantify uncertainty in daily predictions of expected reporting of new cases, enabling identification of new trends in surveillance data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Laboratory Directed Research and Development project XX01, Los Alamos National Laboratory, supported Y.T.L for carrying out early development of mechanistic models and the feasibility studies of regional Bayesian statistical inference. Y.T.L., C.S., J.R., G.T., S.C., and W.S.H. were supported by the US Department of Energy (DOE) Office of Science through the National Virtual Biotechnology Laboratory, a consortium of national laboratories (Argonne, Los Alamos, Oakridge, and Sandia) focused on responding to COVID-19, with funding provided by the Coronavirus CARES Act. J.N., E.M., and R.G.P. were supported by a grant from the National Institute of General Medical Sciences of the National Institutes of Health (R01GM111510). A.M. was supported by the 2020 Mathematical Sciences Graduate Internship program, which is sponsored by the Division of Mathematical Sciences of the National Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study does not require IRB/ethics committee approvals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for daily inference was extracted from the New York Times repository https://github.com/nytimes/covid-19-data. The results of the daily inference will be deposited in our GitHub repository: https://github.com/lanl/COVID-19-Predictions https://github.com/nytimes/covid-19-data https://github.com/lanl/COVID-19-Predictions